title: Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4.
abstract: This report describes a patient with metastatic malignant melanoma treated with recombinant human interleukin 4 who developed vitiligo and severe Graves' Disease after therapy. The patient has experienced complete remission of melanoma for 49+ months. The association of antitumor response, vitiligo and thyroid disorders is reviewed.
authors.affiliation: Department of Medicine/Medical Oncology, University of Texas Health Science Center at San Antonio, 78284 USA.
authors.forename: G R
authors.initials: GR
authors.lastname: Weiss
authors.forename: S H
authors.initials: SH
authors.lastname: Fehrenkamp
authors.forename: L K
authors.initials: LK
authors.lastname: Tokaz
authors.forename: M C
authors.initials: MC
authors.lastname: Sunderland
mesh_terms: D000328:Adult; D005260:Female; D006111:Graves Disease / Q000139:chemically induced*; D006801:Humans; D015847:Interleukin-4 / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy; D014820:Vitiligo / Q000139:chemically induced*
chemical_list: D011994:Recombinant Proteins; D015847:Interleukin-4